Lassa vaccine - Janssen Vaccines/University of Oxford
Latest Information Update: 28 Oct 2022
At a glance
- Originator University of Oxford
- Developer Janssen Vaccines; University of Oxford
- Class Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Lassa fever
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Lassa-fever(Prevention) in United Kingdom
- 29 Sep 2018 Preclinical trials in Lassa fever (Prevention) in United Kingdom (unspecified route)
- 27 Sep 2018 Janssen Vaccines & Prevention B.V., the Coalition for Epidemic Preparedness Innovations and The Jenner Institute at the University of Oxford enter into a collaboration to develop a vaccine against Lassa fever